Skip to main content

Table 5 Comparison of the incidence of adverse reactions after medication between two groups

From: Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19

 

Azvudine(n = 521)

Paxlovid(n = 207)

P value

Shock

51 (9.8)

24 (11.6)

0.557

Acute kidney injury

15 (2.9)

6 (2.9)

1.000

Deep vein thrombosis

5 (1.0)

6 (2.9)

0.110

Gastrointestinal bleeding

13 (2.5)

7 (3.4)

0.683

Diarrhea

13 (2.5)

3 (1.4)

0.556

Nausea and vomiting

1 (0.2)

0 (0.0)

1.000

Oral ulcers

1 (0.2)

0 (0.0)

1.000

Constipation

1 (0.2)

0 (0.0)

1.000

Erythra

1 (0.2)

0 (0.0)

1.000

Myocardial injury

38 (7.3)

28 (13.5)

0.012

Liver function abnormalities

78 (15.0)

40 (19.3)

0.185

Elevated D-dimer levels

61 (11.7)

25 (12.1)

0.991

Total adverse reactions

186 (35.7)

90 (43.5)

0.062